Catalent buys into new antibody tech; Mousera raises $20M;

> Catalent ($CTLT) has inked a deal with Excelimmune to get its hands on some new antibody technology, allowing the company to better manufacture combination therapies. More

> Startup Mousera raised $20 million to advance its ambitions of using Big Data to improve preclinical drug development. Story

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.